Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 24
- Registration Number
- NCT03628066
- Locations
- 🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇺🇸Saddleback Memorial Medical Center, Laguna Hills, California, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
Fulvestrant in Metastatic Breast Cancer
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 30
- Registration Number
- NCT03591549
Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT03475758
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT03450109
- Locations
- 🇺🇸
Pinnacle Research LLC, Anniston, Alabama, United States
🇺🇸South Florida Medical Research, Aventura, Florida, United States
🇺🇸Clinical Research Center of Flordia, Pompano Beach, Florida, United States
Neoadjuvant Goserelin for Triple Negative Breast Cancer
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Kasr El Aini Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT03444025
Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Norwegian School of Sport Sciences
- Target Recruit Count
- 23
- Registration Number
- NCT03440879
- Locations
- 🇳🇴
Norwegian School of Sport Sciences, Oslo, Norway
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- National Cancer Center, Japan
- Target Recruit Count
- 180
- Registration Number
- NCT03423199
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇨🇳Sun Yat-Sen Cancer Center, Taipei, Taiwan
🇯🇵Chiba Cancer Center, Chiba, Japan
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 257
- Registration Number
- NCT03272477
- Locations
- 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 502
- Registration Number
- NCT03096847
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 612
- Registration Number
- NCT03070886
- Locations
- 🇺🇸
Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸MyMichigan Medical Center Saginaw, Saginaw, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.